Birchview Capital’s Arcus Biosciences RCUS Stock Holding History

Birchview Capital’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25,889	Closed	-$559K	–	83
2026 Q1	$559K	Buy	+25,889	New	+$559K	0.32%	53

Other funds holding RCUS

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Birchview Capital's RCUS Position: Q2 2026 in Review

Birchview Capital sold out of Arcus Biosciences (RCUS) in Q2 2026, closing a stake of 25,889 shares — an estimated $559K sold.

Birchview Capital first reported a position in RCUS in Q1 2026 and held it in 1 quarter. The position peaked at $559K in Q1 2026. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

Birchview Capital reported no remaining Arcus Biosciences position as of Q2 2026 after selling out during the quarter.
Birchview Capital sold 25,889 Arcus Biosciences shares in Q2 2026, an estimated $559K.
Birchview Capital first reported a position in Arcus Biosciences in Q1 2026 and held it in 1 quarter.
Birchview Capital's Arcus Biosciences position peaked at $559K in Q1 2026.
232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.